Objective: To investigated whether the use of edaravone affected the relationship between uric acid levels and outcome at 90 days in patients with acute ischemic stroke. Methods: Consecutive ischemic stroke patients with modified Rankin Scale (MRS) scores <2 admitted within 24 h were evaluated by retrospective analysis. The patients were divided into low uric acid (≤333 μmol/L) group and high uric acid (>333 μmol/L) group according to the median uric acid level (333 μmol/L) as a cutoff. And, compared the clinical characteristics and favorable outcomes (MRS <2) in the 2 groups at 90 days. The relationship between uric acid levels and 90-day stroke outcome in patients with or without edaravone treatment was further investigated. Results: The high uric acid group had a higher proportion of men, hypertension, atrial fibrillation, and cardioembolic stroke than the low uric acid group. The high uric acid group also had a higher proportion of patients with MRS <2 at 90 days (P=0.013), however, However, there was no independent correlation between uric acid and good outcome indicators in multivariate analysis (OR 1.30, 95% CI: 0.94–1.71). In subgroup analysis, the high uric acid group without edaravone exhibited a higher proportion of patients with MRS <2 at 90 days than the low uric acid group (OR 2.87, 95% CI: 1.20–7.16), however, the high uric acid group with edaravone did not exhibit this difference. Conclusion: In acute ischemic stroke, the favorable association between high uric acid levels and outcome at 90 days was not evident in patients treated with edaravone.